Remarkably, according to the recent meta-analysis of clinical trials, GLP1 agonists and SGLT2 inhibitors significantly reduced cardiovascular outcomes in patients with type 2 diabetes [181,182,183]. Here, SLC5A2 is linked to type 2 diabetes mellitus.